7:05 am QLT Inc announces positive preliminary results from Phase 1b retreatment trial of QLT091001 in subjects with Leber Congenital Amaurosis and Retinitis Pigmentosa due to mutations in LRAT or RPE65; preliminary results showed clinicall
View todays social media effects on QLTI
View the latest stocks trending across Twitter. Click to view dashboard